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Abstract Kaposi’s sarcoma-associated herpesvirus encodes a
chemokine called vMIP-II that has been shown to be a broad
range human chemokine receptor antagonist. Two N-terminal
peptides, vMIP-II(1^10) and vMIP-II(1^11)dimer (dimerised
through Cys11) were synthesised. Both peptides are shown to
bind the CXC chemokine receptor 4 (CXCR4). vMIP-II(1^10)
was 1400-fold less potent than the native protein whilst the
vMIP-II(1^11)dimer was only 180-fold less potent. In addition,
both peptides are CXCR4 antagonists. Through analysis of non-
standard, long mixing time two-dimensional nuclear Overhauser
enhancement spectroscopy experiments, 13C relaxation data and
amide chemical shift temperature gradients for the N-terminus of
vMIP-II, we show that this region populates a turn-like structure
over residues 5^8, both in the presence and absence of the full
protein scaffold. This major conformation is likely to be in fast
exchange with other conformational states but it has not
previously been detected in monomeric chemokine structures.
This and other studies [Elisseeva et al. (2000) J. Biol. Chem. 275,
26799^26805] suggest that there may be a link between the
structuring of the short N-terminal chemokine peptides and their
ability to bind their receptor. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Immune cell tra⁄cking comprises circulation, homing and
adhesion, extravasation and recirculation of discrete popula-
tions of leukocytes between the blood vessels, lymph and
lymphoid organs [1]. An entire superfamily of chemoattrac-
tant cytokine (chemokines) proteins and their receptors are
involved in the molecular regulation of tra⁄cking [2]. Chemo-
kine activities on leukocyte sub-populations are mediated
through the binding and activation of seven transmembrane
helix G-coupled receptors and nine distinct functional human
CC chemokine receptors (CCR(1^9)) and ¢ve CXC chemo-
kine receptors (CXCR(1^5) have been identi¢ed [3]. The che-
mokines therefore play a pivotal role in the control of leuko-
cyte chemotaxis and represent attractive targets for the
blockade of in£ammatory disease progression [4]. They are
however also targets for viral agents that attempt to subvert
the normal host immune response. Kaposi’s sarcoma (KS) is a
tumour-like lesion that has become frequent in immunode¢-
cient individuals [5]. KS-associated herpesvirus is the infec-
tious agent responsible for KS and interestingly it has been
found to encode several proteins that have direct human im-
mune system counterparts [6]. In particular, two open reading
frames code for CC chemokine-like proteins that have ap-
proximately 40% identity to the human CC chemokines.
One of these, vMIP-II, has been shown to bind and block
receptors belonging to the CXC, CC and XC class, blocking
the normal calcium response elicited through receptors CCR1,
CCR2, CCR5, CCR8, CXCR4 and XCR1 [7,8]. vMIP-II is a
potent agonist of CCR3 [9] and also stimulates weak activity
through the CXCR2 (IL-8B) receptor [7].
The structural basis for promiscuous receptor recognition is
not well understood. The chemokine structures solved to date
are remarkably homogeneous, containing a central core of
three L-strands and an overlying C-terminal K-helix [2]. In
the monomeric subunits, the strands are preceded by a disor-
dered N-terminus, the CXC or CC disulphide motif and an
extended loop (termed N-loop). Many structure/function stud-
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ies aimed at characterising regions of the chemokine fold that
are important for function have concluded that the N-termi-
nus, the disulphide motif and the N-loop are essential for
binding and triggering of the receptor [10]. Modi¢cations
and deletions within these regions have generated analogues
that still bind but do not signal and so act as receptor antag-
onists [11]. It is within these regions that vMIP-II shows the
greatest divergence from its closest human CC chemokine rel-
ative MIP-1K and it may be the case that these regions control
the promiscuous receptor binding.
The N-terminus, the disulphide motif and the N-loop are
essential for binding and triggering of the receptor and are the
least well de¢ned regions of the chemokine structure. There-
fore in this study we have focused on the N-terminus of
vMIP-II (vMIP-II(1^10)) both in the absence and presence
of the remaining protein sca¡old. These studies reveal that
the N-terminus alone is su⁄cient for CXCR4 receptor binding
and furthermore it is a receptor antagonist. The formation of
a dimer of residues (1^9) of SDF-1 was recently shown to
increase CXCR4 binding when compared to monomeric
(1^9) [12] and we go on to show that the binding is increased
by the formation of a dimer consisting of the ¢rst 11 residues
of the N-terminus of vMIP-II, disulphide linked through
Cys11. However in this case the binding is two-fold stronger
than the SDF-1(1^9)dimer binding. This has prompted a de-
tailed nuclear magnetic resonance (NMR) study of vMIP-
II(1^10) using two-dimensional (2D) methods, long mixing
time 2D nuclear Overhauser enhancement spectroscopy (NO-
ESY) experiments, the temperature gradients of amide proton
chemical shifts and 13C relaxation data. We show that
although the vMIP-II(1^10) peptide is £exible, the NMR
data reveals a major family of structures consisting of a
turn, both in the free peptide and the full vMIP-II structure
(also presented herein). This feature is not observed during the
application of standard NMR methods to solving the full
protein structure. The turn is stabilised principally by the
packing of the Trp5 (tryptophan is not observed in any other
chemokine N-terminus) against the side chains of both Arg7
and Pro8.
2. Materials and methods
2.1. Chemical synthesis of vMIP-II and peptides (1^10) and
(1^11)dimer
Peptides were synthesised as described previously [13]. The (1^11)
peptide was dimerised via a disul¢de bridge formed by gentle oxida-
tion of the cysteines using 10% Me2SO in water.
2.2. Cell culture
The CEM cell line was purchased from the American Type Culture
Collection (Rockville, MD, USA) and maintained in RPMI 1640
medium supplemented with 10% foetal calf serum.
2.3. Chemotaxis
Migration of CEM cells was performed with disposable Transwell
trays (Costar, Cambridge, MA, USA, with 6.5 mm diameter chambers
and a membrane pore size of 3 Wm). The agonist/antagonist, in
HEPES-bu¡ered RPMI 1640 supplemented with 10 mg/ml31 bovine
serum albumin (0.6 ml) was added to the lower well, and 0.1 ml of
CEM cells (1U107 ml31) in the same medium without agonist was
added to the upper wells. After 2 h, cells that migrated to the lower
wells were counted. Chemotactic migration was determined by the
subtraction of cells migrated in medium alone. All assays were per-
formed in duplicate.
2.4. vMIP-II receptor binding
Competition for binding of 125I-labelled SDF-1 to CEM cells was
carried out as described in [11].
2.5. NMR studies of vMIP-II(1^10)
1H NMR spectra of the vMIP-II(1^10) were acquired at 600 MHz
using a Varian Unity spectrometer. Double-quantum-¢ltered corre-
lated spectroscopy (DQF-COSY), total correlation spectroscopy
(TOCSY) and NOESY spectra were used to fully assign the 1H res-
onances. All spectra were acquired at 8‡C in 90% H2O/10% D2O or
99.99% D2O. For the determination of the solution conformation of
vMIP-II(1^10), NOESY spectra at mixing times of 125, 300, 400 and
500 ms were used and build-up rates were found to be linear over this
range. {1H}-13C nuclear Overhauser enhancement (NOE) experiments
that focused on CK protons were performed at 600 MHz on a sample
of vMIP-II(1^10) at 281 and 308 K.
2.6. Structure determination of vMIP-II(1^10)
NOE peaks picked from the 8‡C, 500 ms NOESY data set were
integrated and converted to distance restraints. The restraints were
grouped as strong, medium, weak and very weak classes correspond-
ing to upper distance restraints of 2.8, 3.5, 4.5 and 5.5 Aî , respectively.
Upper distance restraints were corrected with centre averaging where
appropriate for non-stereospeci¢cally assigned methylene protons. A
total of 105 NOEs were assigned corresponding to 40 sequential,
13 short range and 52 intra residue restraints. Structure calculations
were performed using the simulated annealing protocols within
XPLOR [14] and utilised 4000 steps of high temperature dynamics
(1000 K) and 4000 cooling steps to a ¢nal temperature of 298 K.
The NOE force constant was set at 50 kcal mol31 Aî 2. Out of 100
calculated structures, 55 were selected that showed no NOE violations
s 0.2 Aî .
2.7. NMR studies of vMIP-II (1^71)
NMR experiments were performed on Varian Unity 600 and Var-
ian Inova 500 and 600 MHz spectrometers at temperatures ranging
from 8 to 35‡C. Samples for structural studies were 2 mM protein,
20 mM sodium acetate, 1 mM sodium azide and 1 mM DSS at pH
5.0. Standard pulse sequences were employed for resonance assign-
ments: DQF-COSY, TOCSY and NOESY. TOCSY spectra were ac-
quired with mixing times of 55 ms and NOESY spectra with mixing
times of 50, 150, 300 and 500 ms (300 and 500 ms datasets were used
for the analysis of residues 1^10 only).
2.8. Structure calculations for vMIP-II(1^74)
The solution structure of vMIP-II was determined as described
previously [11] using the dynamic simulated annealing protocol within
the program X-PLOR [14]. A total of 777 NOEs were used in the
structure calculations comprised of 201 long range (Mi3jMv 5), 57
short range (4v Mi3jMv 1), 191 sequential (Mi3jM= 1) and 306 intra
residues (i = j). A set of 38 ¢nal structures was selected from the 40
re¢ned structures on the basis of lowest total energy and agreement
with the experimental data. Analysis of the (P, i) backbone torsion
angles and quality of the structures was made using the program
PROCHECK [15].
3. Results and discussion
3.1. Receptor binding of the vMIP-II N-terminal peptides
Previously several peptides SDF(1^9) and SDF(1^9)dimer
[12] and several vMIP-II N-terminal peptides (including (1^
10), (6^18) and (1^21)) have been shown to have weak binding
to CXCR4 [16]. In this study residues 1^10 of the N-terminus
of vMIP-II (-LGASWHRPDK-), vMIP-II(1^10) and (1^11)
(-LGASWHRPDKC-) and the vMIP-II(1^11)dimer were syn-
thesised and tested for chemotaxis and receptor binding. CEM
cells were used to determine the binding of the vMIP-II N-
terminal peptides to CXCR4. The competition for binding of
125I-labelled native SDF-1 by unlabelled SDF-1, SDF(1^9),
SDF(1^9)dimer, vMIP-II(1^10) and vMIP-II(1^11)dimer is
shown in Fig. 1A. SDF(1^9) shows the weakest binding and
competition by the SDF-1(1^9) is incomplete at the concen-
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trations tested. An accurate Kd could not be calculated but
was estimated as 1500-fold less than wild-type binding [12].
However, the vMIP-II(1^10) shows stronger binding than the
SDF(1^9) monomeric counterpart and binds 1400 times less
tightly than SDF-1. The most dramatic increases in binding
come from the dimeric forms, the SDF(1^9)dimer and vMIP-
II(1^11)dimer. In the study by Loetscher et al. [12], the
SDF(1^9)dimer showed only 82-fold less binding than native
SDF-1. In the present assays the binding is shown to be 300-
fold weaker than SDF-1 and slightly lower than seen before.
However, the binding of vMIP-II(1^11)dimer is only 180-fold
less than SDF-1 and is the most tightly binding small peptide
that we have observed to date. As controls, the N-terminal
peptides from MDC, IP-10, eotaxin and eotaxin-2 were syn-
thesised and also tested for competitive binding of 125SDF-1
to CXCR4. Data for MDC is shown in Fig. 1A. This is
representative of each peptide tested and shows that no re-
ceptor binding is observed. This indicates that binding of
short peptides to CXCR4 is not a general property of either
CXCR4 or this type of short peptide ligand.
3.2. vMIP-II(1^10) does not induce chemotaxis
Since native vMIP-II is an antagonist for CXCR4, we next
tested whether the antagonistic properties were retained by the
N-terminal fragments. Fig. 1B shows chemotaxis inhibition
data for vMIP-II(1^10) and SDF-(1^9)dimer. vMIP-II(1^10)
did not induce chemotaxis of CEM cells whereas SDF-
(1^9)dimer induced a dose-dependent chemotaxis. Therefore,
despite receptor binding, the N-terminal peptide does not ap-
pear to activate the CXCR4 receptor and importantly, retains
its antagonist properties.
3.3. 3D structure of vMIP-II (1^10)
1H NMR assignments for the vMIP-II(1^10) were made
using standard 2D NMR techniques. Subsequently, a total
of 105 NOEs could be assigned from an 8‡C NOESY corre-
sponding to 40 sequential, 13 short range and 52 intra residue
restraints. The principal contacts that de¢ne the 3D structure
are the 13 short range NOEs between the Trp5 ring and the
side chain of Arg7/Pro8, between Arg7 and Asp9, Val3 and
Trp5 and Ser4 and His6. A total of 100 structures were calcu-
lated of which 55 were selected that contained no NOE re-
straint violations s 0.2 Aî . Examination of the 55 structures
showed that they are clustered with almost identical backbone
conformation over residues 5^8 (Fig. 2). The formation of a
small hydrophobic pocket appears to centre around a trypto-
phan staple between Trp5 and Pro8. For these residues, sev-
Fig. 1. Receptor binding of vMIP-II and SDF-1 based N-terminal
peptides and chemotaxis inhibition by vMIP-II(1^10). A: Competi-
tion for speci¢c binding of 125I-SDF-1 (4 nM) to CEM cells by
SDF-1 (open circle), SDF(1^9) monomer (open triangle), SDF-
(1^9)dimer (closed triangle), vMIP-II(1^10) (open square), vMIP-
II(1^11)dimer (closed square) and N-MDC (square with cross). The
data for the N-terminal peptides of IP-10, eotaxin and eotaxin-2 are
not shown. The results are representative of duplicate experiments.
B: CEM cell migration induced by concentrations of SDF-
(1^9)dimer (closed circle) and the antagonist vMIP-II(1^10) (open
triangle). Data are the means of þ S.D. of duplicate determinations
from two separate experiments.
Fig. 2. Solution structure of the vMIP-II(1^10). A bundle of 55 cal-
culated structures is shown superimposed on the average structure.
Residues Trp5 through to Pro8 corresponding to the region of par-
tial structuring are annotated.
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eral short range (i, i+3) NOEs were detected between the side
chain ring protons of Trp5 and the proline ring. In addition (i,
i+2) NOEs between backbone and side chain protons of Arg7
to the ring of Trp5 de¢ne the earlier portion of the chain. It
should be stressed however that our use of restraints in these
calculations is only giving us information on the folded form
and this is likely to be in equilibrium with numerous unfolded
states that we are not detecting with NOESY experiments (i.e.
GR36f averaging of the NOE may bias the short distance con-
tacts that most likely arise in a folded form). Analysis of the
backbone CKH and NH (Fig. 3A,B) chemical shifts shows
that little or no deviation is seen for the CKH chemical shifts
but both His6 and Arg7 show deviation in the more sensitive
NH chemical shifts. Backbone 3JHNHA coupling constants are
mostly averaged through the peptide (6^8 Hz) with the excep-
tion of Arg7 that shows a reduced coupling constant (5.3 Hz).
Natural 13C abundance {1H}-13C NOE experiments for
vMIP-II(1^10) were also recorded and the data analysed spe-
ci¢cally for the relaxation of the backbone CK protons. Fig.
3D compares values measured at 30 and 8‡C. A smaller NOE
(R) value indicates reduced motion and a larger R indicates
greater motion on a picosecond timescale. At 30‡C residues
Ala3, Ser4, Asp9 and Lys10 and the ends of the peptide show
increased values of R whilst the central four residues show
reduced values. This suggests that the ends of the peptide
are somewhat more £exible than the central positions as ex-
pected. When the temperature is reduced to 8‡C all of the
NOE values drop, due in part to an increase in the viscosity
of the water. However some increases are particularly prom-
inent, i.e. for Arg7 and Asp9. The overall dip in the NOE
values at the centre of the peptide versus the ends also in-
creases signi¢cantly compared to the 30‡C data, indicating
an increase in overall structuring of the central portion of
the peptide.
A recent study by Andersen et al., [17] shows extensively
that the vN/vT versus chemical shift deviation (CSD) of the
amide proton correlated well with partial structuring of the
peptides which then become increasingly randomised upon
warming. In general ¢ts with slopes between 38 and 20 ppt/
‡C and high correlation coe⁄cients (R2s 0.7) were observed
for short peptides with well characterised structuring at lower
temperatures. To measure the vN/vT values for vMIP-II-
(1^10), a series of 1D spectra were measured at a range of
temperatures between 8 and 30‡C. The CSDs for vMIP-II-
(1^10) were derived from the lowest temperature set included
(8‡C) and were corrected according to Anderson [17] and
Wishart [18]. Fig. 3E shows the resulting plot of CSD versus
vN/vT for vMIP-II(1^10). The majority of residues show little
CSD and large vN/vT gradients and lie in a cluster with the
clear exception again of His6 and Arg7. When ¢t with linear
regression, we obtained a slope of 39.6 ppt/‡C and a corre-
lation coe⁄cient R of 0.67 giving the expected correlation for
a minimally structured protein fragment.
3.4. 3D structure of the N-terminus within vMIP-II(1^71)
We have solved the full 3D structure of vMIP-II(1^71) at
30‡C and deposited the coordinates, restraints and structural
statistics in the Brookhaven PDB with access number 4914.
At 30‡C and at 150 ms mixing times, we observed no short
range NOEs within the N-terminus with the exception of two
extremely weak NOEs between the Trp5 ring and the NHs of
Pro8. However NOESY experiments at 30 and 8‡C with
500 ms mixing times showed a set of short range NOEs within
the N-terminus similar to those observed in the (1^10) pep-
tide. In several cases spectral overlap and poorer spectral
quality prevented an NOE comparison being made in the
8‡C dataset of vMIP-II(1^71). Nevertheless these experiments
con¢rm that the structuring we observed in the free peptide
may also be detected with long mixing time experiments in the
context of the full protein structure. The remaining 3D struc-
ture of vMIP-II was broadly con¢rmatory of other chemokine
structures and in the absence of thorough structure/function
data we have not given a comparison of vMIP-II with other
chemokines that share the similar receptors (eotaxin CCR3,
SDF-1 CXCR5). A detailed comparison has been presented
elsewhere in the literature [19].
Little or no binding has been observed between the N-ter-
Fig. 3. NMR structural characterisation of vMIP-II(1^10). A: CKH
CSD from random coil values. B: Measured three bond HN^HA
(3JHNHA) coupling constant. C: NH CSD from random coil values.
D: 1H-{13C} NOE at 30 and 8‡C. E: Plot of amide temperature co-
e⁄cients versus amide CSD. The line shows the best ¢t to the data
with linear regression with slope 39.6 ppt/‡C and a correlation coef-
¢cient of 0.67.
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minal fragments of chemokines and the chemokine receptors
suggesting that numerous interactions are required to ensure
strong binding. The exceptions to this rule are the N-terminal
domains of vMIP-II and SDF-1 that showed binding to
CXCR4, albeit weakly. Both peptides bound to CXCR4
more strongly when they were disulphide linked to form a
dimer. For SDF-1(1^9) this improved the binding from
1500-fold less than native SDF-1, to only 82-fold less for
SDF-1(1^9)dimer. The vMIP-II(1^11)dimer shows the stron-
gest binding yet observed for an N-terminal fragment. This
may be a purely statistical factor (i.e. there is essentially dou-
ble the concentration of N-terminal peptide) or, as we have
described previously, one half of the dimer may mimic the
N-loop of the full protein and interact with a second part
of the receptor [20]. As seen in Fig. 1A, our success in steadily
increasing the binding of short peptide sequences to CXCR4
warrants further investigation into the factors dictating the
binding of this region.
In this report we have also shown by a combination of
NMR structure determination methods that the vMIP-II-
(1^10) samples a turn-like structure through residues 5 to 8.
The extension of this approach to the use of long mixing time
NOESY experiments with the full length protein has also
allowed the identi¢cation of the same NOE patterns within
the N-terminus of native vMIP-II(1^71). Structuring within
an N-terminal peptide from the SDF-1 sequence has also re-
cently been reported [20] over residues 5^8. Both of these
studies have employed long mixing time NOESY experiments
aimed at allowing su⁄cient NOE build-up in the partially
structured regions that have e¡ective short correlation times
and slow NOE build-up rates. It is now an open question as
to whether binding may be attributable to an increased pro-
pensity for a constitutive structure in this region. This is part
of ongoing studies in our laboratory which continue to ad-
dress the role of the N-terminus in receptor binding.
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